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Autism spectrum disorders (ASDs) are a group of complex neurodevelopmental
conditions that present in early childhood and have a current estimated prevalence of
about 1 in 68 US children, 1 in 42 boys. ASDs are heterogeneous, and arise from
epigenetic, genetic and environmental origins, yet, the exact etiology of ASDs still remains
unknown. Individuals with ASDs are characterized by having deficits in social interaction,
impaired communication and a range of stereotyped and repetitive behaviors. Currently,
a diagnosis of ASD is based solely on behavioral assessments and phenotype. Hundreds
of diverse ASD susceptibility genes have been identified, yet none of the mutations found
account for more than a small subset of autism cases. Therefore, a genetic diagnosis is
not yet possible for the majority of the ASD population. The susceptibility genes that
have been identified are involved in a wide and varied range of biological functions.
Since the genetics of ASDs is so diverse, information on genome function as provided by
transcriptomic data is essential to further our understanding. Gene expression studies
have been extremely useful in comparing groups of individuals with ASD and control
samples in order to measure which genes (or group of genes) are dysregulated in the
ASD group. Transcriptomic studies are essential as a key link between measuring protein
levels and analyzing genetic information. This review of recent autism gene expression
studies highlights genes that are expressed in the brain, immune system, and processes
such as cell metabolism and embryology. Various biological processes have been shown
to be implicated with ASD individuals as well as differences in gene expression levels
between different types of biological tissues. Some studies use gene expression to
attempt to separate autism into different subtypes. An updated list of genes shown to be
significantly dysregulated in individuals with autism from all recent ASD expression studies
will help further research isolate any patterns useful for diagnosis or understanding the
mechanisms involved. The functional relevance of transcriptomic studies as a method
of classifying and diagnosing ASD cannot be underestimated despite the possible
limitations of transcriptomic studies.
Keywords: autism spectrum disorders (ASD), gene expression, immune system, lymphoblastoid cell lines,
monozygotic twins, Fragile X Syndrome, neurogenesis and inflammation
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BACKGROUND
Autism spectrum disorders (ASDs) are a group of complex
neurodevelopmental conditions that present in early childhood.
Individuals with ASDs are characterized by having deficits in
social interaction, impaired communication and a range of
stereotyped and repetitive behaviors (Lord et al., 1994). In 2012,
ASD has a current estimated prevalence of about 1 in 68 US
children aged 8 years; estimated prevalence was significantly
higher among boys (23.6 per 1000) than among girls (5.3 per
1000) (Christensen et al., 2016). ASDs are heterogeneous, and
arise from epigenetic, genetic and environmental origins. The
exact etiology of ASDs still remains unknown andASD cases with
a genetic etiology only collectively account for 10–20% at most
(Abrahams and Geschwind, 2008). The precise role of genetics
in the pathogenesis of ASD remains unclear. On the one hand,
there are several hints that genetics play a role (Wang et al., 2009).
For example, there are much higher concordance rates of ASDs
in monozygotic twins (70–90%) than dizygotic twins (0–10%)
(Abrahams and Geschwind, 2008). Similarly, the recurrence risk
in families ranges from 12.9% (Sandin and Reichenberg, 2014) to
18.7% (Ozonoff et al., 2011; Yuen et al., 2015). Furthermore, more
than 100 ASD-susceptibility genes have already been identified
(Yuen et al., 2015). On the other hand, these specific genetic
mutations account for less than 8% of cases (Alter et al., 2011).
There are a number of explanations for this ambiguity ranging
from gene-gene interactions, to the heterogeneity of the disease,
to epigenetic factors (Alter et al., 2011). Broad gene expression
screening of children diagnosed with ASD is one approach
toward mitigating the challenge of the heterogeneity of ASD by
separating those diagnosed with ASD into subclasses according
to gene expression profiles.
In the most recent comprehensive review of gene expression
studies in ASD in 2012, Voineagu et al. surveyed 10 major
mRNA studies across two types of samples [lymphoblastic (LBL)
and post-mortem brain tissue]. They found that transcriptome
analysis was more efficient than DNA studies in identifying
differences between ASD and controls. Focusing on human
mRNA studies since 2011 in English that monitor up or down
regulation of multiple genes in ASD, without comparing to
other disorders, we find that 27 major new studies have been
published. By considering both single gene studies and more
complex studies looking at pathways, researchers will be able to
compare their findings to individual lists of genes but also to
attempt to place their findings in a broader context by looking
at pathway networks implicated in ASD. For example, if a
researcher identifies a single specific gene to be upregulated in
Abbreviations: ADI-R, autism diagnostic interview revised; ANOVA, analysis
of variance; ASD, autism spectrum disorders; asdMO, mothers having children
with ASD; CNV’s-copy number variants; DAVID, Database for Annotation,
Visualization and Integrated Discovery; DSM-5, Diagnostic and Statistical Manual
ofMental Disorders, Fifth Edition; ELISA, Enzyme-Linked Immunosorbent Assay;
IFNγ, interferon gamma; IL, interleukin; LCL, lymphoblastoid cell lines; mRNA,
messenger ribonucleic acid; MGAM, maltase glucoamylase; NOS, nitric oxide
synthetase; PCs, Purkinje cells; RT-qPCR, Real-time quantitative polymerase chain
reaction; SAM, significance analysis of microarrays; SNP’s, single nucleotide
polymorphism; TD, typically developing/developed.
a specific type of tissue in ASD, that can then be compared to
other single gene studies across different tissue types to see if
there is consistency in the directionality of regulation and across
tissue types. Additionally, by looking at a variety of networks
and pathways, researchers can see the interaction between
various neurodevelopmental and immune processes. These
studies follow similar methodology to the studies previously
discussed; though some expand to a third tissue type namely,
intestinal biopsy samples.
GENE EXPRESSION STUDIES IN ASD BY
TISSUE TYPE
In reviewing the new gene expression studies since Voineagu’s
paper (Table 1), the classification according to sample source will
prove helpful. Five sample sources were studied: post-mortem
brain, peripheral blood, gastrointestinal tissue, adult olfactory
stem cells, and scalp hair follicles. Before beginning with the
post-mortem brain tissue studies, it is relevant to mention gross
pathological and radiological brain findings that might provide
context for the brain-related expression findings.
Neurological Background
Evidence for neurological involvement in ASD can be divided
into neuroimaging and post-mortem pathology.
Neuroimaging
Neuroimaging studies of children with autism have revealed
abnormal brain overgrowth in prefrontal, temporal and
amygdala regions and abnormal functional asymmetry and
activation in the cortex and cerebellum (Chow et al., 2012).
Neuroimaging techniques such as functional MRI has shown
altered patterns of functional specialization in autism in several
domains of thinking, such as cognitive, linguistic, social,
and visuospatial processing in children and adults with ASD
(Maximo et al., 2014). Impaired functional connectivity may
demonstrate inefficiency in maximizing network connections
to execute tasks, yet the findings of over-connectivity have
been interpreted to reflect hyper-specialized, rather than more
efficient connectivity. Based on the abundance of information,
inefficient connectivity may be the hallmark of ASD.
Pathology
Pathology on postmortem brains from subjects diagnosed with
ASD have demonstrated abnormalities in neuronal organization
of the cerebral cortex and decreased number of Purkinje cells
in the cerebellum (Garbett et al., 2008). Children between 2
and 4 years old diagnosed with ASD have been found to have
increased total cerebral gray and white matter, excess neurons in
the pre-fontal cortex, and an increase in brain weight at autopsy
(Courchesne et al., 2011; Hazlett et al., 2011). In some children
diagnosed with ASD, the rate of head growth and brain growth is
exceptionally rapid during the first few years of life. Additionally,
although most children with autism are born normocephalic,
during the first years of life, 15–20% will develop macrocephaly
(Lainhart et al., 2006). However, by late adolescence and early
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TABLE 1 | Gene Expression Studies of Autism: 2011 onwards (Year chosen since Voineagu et al. review paper is from 2012).
Study Number of samples Tissue source Number of dysregulated
genes listed
Alter et al., 2011 82 children with autism (mean: 5.5 years SD 2.1 p
< 0.0001) and 64 controls (mean: 7.9 years SD 2.2
p < 0.0001)
PBL Children w/autism/Children w/younger
fathers: 2093 significantly downregulated &
641 significantly upregulated genes; Children
w/older fathers: Children w/younger fathers:
1476 significantly downregulated & 764
significantly upregulated genes; 593 genes
were downregulated and 145 genes were
upregulated in both children with autism and
children of with older fathers
Anitha et al., 2012 9 autism patients ant 8 controls ACG, MC, THL 28 genes showed brain region-specific
reduced expression in autism
Chien et al., 2013 PART I: Conducted comparative total gene
expression profiling analysis between 16 male
patients with ASD (age range 4–18 years) and 16
male control subjects (age range 18–67 years);
PART II: compared transcript level of one particular
gene (FOXP1) between 83 male patients with ASD
and 83 male healthy controls
LCL derived from the EBV transformation
of lymphocytes of peripheral blood
202 genes were differentially expressed in the
ASD group, including 89 upregulated and
113 downregulated
Chow et al., 2012 16 from young postmortem males (2–14 years;
autism = 9, control = 7) and 17 adult males (15–56
years, autism = 6, control = 11)
DLPFC 2017 genes across all autistic and control
cases independent of age
Féron et al., 2016 9 adults with severe autism and low to very low
developmental disabilities, plus two adults with mild
or moderate autism and no or mild cognitive abilities
(Asperger syndrome or high functioning autism)
paired with 11 age and gender matched controls
Adult nasal olfactory stem cells 156 genes that were differentially expressed
in at least one ASD patient, of which 31 were
dysregulated in more than a third of the
cohort
Ginsberg et al., 2012 9 autism and 9 control subjects BA19 (occipital) brain tissues 876 unique, annotated genes differently
expressed between autistic and control
brains
Glatt et al., 2012 60 infants and toddlers at risk for ASDs (autistic
disorder and pervasive developmental disorder), 34
at risk for LD, 17 at risk for DD, and 68 TD children
PBMCs 154 probes showed significant dysregulation
in ASD
Chana et al., 2015 Utilized published microarray data from 30 control
and 27 ASD individuals
DLPFC 3 downregulated genes and 1 upregulated
gene in ASD samples
Ivanov et al., 2015 30 subjects with idiopathic autism (24 male, 6
female) aged 3 to 11 years (mean age of sample
6.86 years) and 30 healthy children age and sex
matched
Peripheral blood 23 differentially expressed genes (10
upregulated, 13 downregulated)
James et al., 2014 13 autism and 13 unaffected control individuals Cerebellar cortex 7 genes
Khan et al., 2014 11 control (4F,7M) and 10 ASD (3F,7M) cases were
examined (Controls ranged between 5 and 16 years
of age, while ASD ranged from 4 to 15 years of age)
CB, BST, CG, ORC, PT, Wer 15 genes showed brain-region specific
dysregulated expression in ASD samples
Kong et al., 2013 20 proband-unaffected sibling pairs (5 probands-sib
pairs were of the same gender, i.e., males, while 15
pairs were of the opposite gender including 12 male
and 3 female probands) and 18 unrelated control
(11 males, 7 females) individuals
Peripheral blood 163 unique genes were significantly changed
between probands and siblings
Kuwano et al., 2011 GROUP 1: 21 Young adults with ASD (17 males and
4 females) aged 26.7 ± 5.5 years, age range: 18-38
years; GROUP 2: 21 age and gender matched
healthy controls aged 27.0 ± 5.5 years, age range:
19–39; GROUP 3: 21 Healthy mothers having
children with ASD (asdMO), aged 44.7 ± 6.7 years,
age range: 33–58 years; GROUP 4: asdMO control,
aged 44.7 ± 6.7 years, age range: 31–59 years
Peripheral blood ASD/control: 19 genes were found to be
significantly dysregulated (18 upregulated
and 1 downregulated); asdMO/asdMO
control: 57 genes were found to be
significantly dysregulated (17 upregulated
and 40 downregulated); 3 genes overlapped
and were dysregulated both in individuals
with ASD and in asdMO
Maekawa et al.,
2015
24 male control subjects (Aged 32.60 ± 3.91) and
18 Autism subjects (16 male, 2 female; aged 25.61
± 4.95)
Scalp hair follicles 1 gene
(Continued)
Frontiers in Neuroscience | www.frontiersin.org 3 January 2017 | Volume 10 | Article 601
Ansel et al. Gene Expression in ASD
TABLE 1 | Continued
Study Number of samples Tissue source Number of dysregulated
genes listed
Prandini et al., 2014 Two separate series of sib-pairs totaling 36 children
and adolescents between 4 and 18 years of age
LCLs none found
Segura et al., 2015 21 adolescents and adults diagnosed as ASD (20
males, 1 female) as well as from 10 healthy controls
(10 males)
Whole blood 3 genes
Stamova et al., 2011 33 boys with AU (mean age 45.3 months; age
range of 31–60 months) and 51 age-matched TD
control boys (mean age 43.3 months; age range
28–57 months)
Whole blood 11 genes
Talebizadeh et al.,
2014
Autistic group included three females (6, 11, and 13
years old) and two males (5 and 12 years old)
diagnosed with classical autism and 5 age and sex
matched unrelated controls
LCL derived RNAs 57 genes
Taurines et al., 2011 51 children with ADHD, 26 children with ASD (19/26
comorbid with ADHD) and 39 TD
Whole blood cells 2 genes
Tian et al., 2011 37 children with autism (32 males, 5 females;
average age 44.2 ± 10 months) compared to 15
typically developing controls (11 males, 4 females;
average age 41.2 ± 6 months)
Whole blood 31 genes
Voineagu and
Eapen, 2013
19 autism cases and 17 controls STG, prefrontal cortex (BA9) and
cerebellar vermis
444 genes showing significant expression
changes in autism cortex samples, 2 genes
differentially expressed in cerebellum
Walker et al., 2013 25 children with a diagnosis of ASD (mean age
5.0862.06 years; 23 male and 2 female, 16 had a
diagnosis of autism; 9 had a diagnosis of autism
spectrum disorder); 3 TD groups: (1) 15 children
with no chronic GI symptoms (mean age 12.263.07
years; 6 male and 9 female); (2) children with a
diagnosis of Crohn’s disease (n = 8, mean age
12.9763.07 years; 3 male and 5 female); (3) children
with a diagnosis of ulcerative colitis (n = 5, mean
age 12.064.0 years; all female)
Tissue specimen from 7 anatomic
locations (from terminal ileum to rectum)
Ileal mucosa: ASD-GI/TD -1409 differentially
expressed transcripts • Colonic mucosa:
ASD-GI/TD -1189 differentially expressed
transcripts: Overlap between both sets
ASD-GI (Ileum and Colon)/ TD -178
transcripts exclusively differentially-expressed
Williams et al., 2011 15 AUT-GI children (mean onset age 13.4+/25.4
months, median age at biopsy 4.5), 7 Control-GI
patients (median age at biopsy 4.0)
Ileum and Cecum 6 genes
Yasuda et al., 2011 35 patients with ASD (mean age 12.9 years ± 12.4
SD) 35 healthy controls (mean age 34.8 years ± 9.7
SD)
LCLs 2 genes
Zhubi et al., 2014 10 ASD and 10 control samples Cerebellar cortex 4 genes
Ziats and Rennert,
2013
Re-analyzed sex-specific gene-expression from a
recent large transcriptomic study (Kang et al.,
2011); N = 57, including 39 with both hemispheres;
age, 5.7 post-conceptual weeks to 82 years; sex,
31 males and 26 females;
Transient prenatal structures and
immature and mature forms of 16 brain
regions (Kang et al., 2011; Table 2)
37 Female and 123 Male genes found to be
differentially expressed by sex, and their brain
region and developmental time point
PBL, Peripheral blood lymphocytes; LCL, lymphoblast cell line; PBMCs, peripheral blood mononuclear cells.
ACG, anterior cingulate gyrus; MC, motor cortex; THL, thalamus; DLPFC, Dorsolateral Prefrontal Cortex; CB, Cerebellar; BST, Brain stem.
CG, Cingulated gyrus; ORC, Orbitofrontal cortex; PT, Putamen; Wer, Wernicke’s; STG, superior temporal gyrus.
LD, language delay; DD, global developmental delay; TD, typically developing.
adulthood, the autistic brain commonly displays neuron loss and
cortical thinning and is no longer enlarged (Kates et al., 2004).
POST-MORTEM BRAIN TISSUE GENE
EXPRESSION STUDIES
With the background provided by the neuroimaging and
pathology findings in mind, gene expression studies in brain
tissue can now be reviewed. There are nine gene expression
studies that look at a variety of brain regions. The studies are
all very small but produced large numbers of genes with variable
expression between ASD and control. Chow et al. analyzed
frozen samples of dorsolateral prefrontal cortex from 16 young
postmortem males (9 autism, 7 control) and 17 adult males (6
autism, 11 control) in order to study age-dependent brain gene
expression (Chow et al., 2012). They found 102 genes, which
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TABLE 2 | Gene expression changes in ASD detected in multiple independent studies in various tissues.
Gene
symbol
Blood/LCL study Brain study Intestinal biopsy study Expression change in ASD
ABHD3 Kong et al., 2013 Garbett et al., 2008 Upregulated
ACTG2 Ziats and Rennert, 2013 Walker et al., 2013 Downregulated
ADM Garbett et al., 2008; Voineagu and
Eapen, 2013
Upregulated
AHI1 Garbett et al., 2008; Voineagu and
Eapen, 2013
Downregulated
ALAD Chow et al., 2012 Walker et al., 2013 Downregulated
ALPK1 Nishimura et al., 2007;
Talebizadeh et al., 2014
Upregulated
ANKRD22 Glatt et al., 2012; Ivanov et al.,
2015
Upregulated in Ivanov et al. Downregulated in
Glatt et al.
ANXA1 Chien et al., 2013 Garbett et al., 2008; Voineagu and
Eapen, 2013; Ziats and Rennert, 2013
Upregulated in Garbett et al. and Ziats et al.
Downregulated in Chien et al.
AQP4 Garbett et al., 2008; Voineagu and
Eapen, 2013
Upregulated
ATF3 Hu et al., 2006 Walker et al., 2013 Upregulated in Hu et al. Downregulated in
Walker et al.
BAG3 Garbett et al., 2008; Voineagu and
Eapen, 2013
Upregulated
C20orf7 Chow et al., 2012; Ginsberg et al., 2012 Downregulated
C5orf16 Garbett et al., 2008; Voineagu and
Eapen, 2013
Downregulated
CCL17 Nishimura et al., 2007 Walker et al., 2013 Upregulated
CD160 Gregg et al., 2008; Enstrom
et al., 2009
Upregulated
CHI3L1 Chien et al., 2013 Garbett et al., 2008 Upregulated in Garbett et al. Downregulated in
Chien et al.
CLIC1 Garbett et al., 2008; Voineagu and
Eapen, 2013
Upregulated
CMKOR1 Nishimura et al., 2007 Garbett et al., 2008; Voineagu and
Eapen, 2013
Upregulated
CNN3 Garbett et al., 2008; Voineagu and
Eapen, 2013
Upregulated
COL4A1 Garbett et al., 2008; Voineagu and
Eapen, 2013
Upregulated
COX7B Ginsberg et al., 2012; Anitha et al.,
2012
Downregulated
CSDA Garbett et al., 2008; Voineagu and
Eapen, 2013
Upregulated
CTNNB1 Kong et al., 2013 Chow et al., 2012 Upregulated in Kong et al. Downregulated in
Chow et al.
CX3CR1 Gregg et al., 2008; Enstrom
et al., 2009
Ziats and Rennert, 2013 Upregulated
CXCL10 Chien et al., 2013 Chow et al., 2012 Upregulated
CXCR4 Chien et al., 2013 Chow et al., 2012 Upregulated
CYC1 Ginsberg et al., 2012; Anitha et al.,
2012
Downregulated
CYFIP1 Nishimura et al., 2007;
Talebizadeh et al., 2014
Upregulated
DLX1 Garbett et al., 2008; Voineagu and
Eapen, 2013
Downregulated
DNASE1L3 Chien et al., 2013 Chow et al., 2012 Downregulated
DRD4 Emanuele et al., 2010; Taurines
et al., 2011
Upregulated in Emanuele et al. Downregulated
in Taurines et al.
(Continued)
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TABLE 2 | Continued
Gene
symbol
Blood/LCL study Brain study Intestinal biopsy study Expression change in ASD
FAM46C Nishimura et al., 2007; Chien
et al., 2013
Upregulated in Chien et al. Downregulated in
Nishimura et al.
FOSL1 Ivanov et al., 2015 Chow et al., 2012 Upregulated in Chow et al. Downregulated in
Ivanov et al.
GAD1 Chien et al., 2013 Zhubi et al., 2014 Downregulated
GADD45B Garbett et al., 2008; Voineagu and
Eapen, 2013
Upregulated
GPR56 Gregg et al., 2008 Ginsberg et al., 2012 Upregulated
GRIA3 Chien et al., 2013 Chow et al., 2012 Downregulated
GZMB Gregg et al., 2008; Enstrom
et al., 2009; Chien et al., 2013
Upregulated
HCK Hu et al., 2006; Chien et al.,
2013; Talebizadeh et al., 2014
Upregulated in Talebizadeh et al.,
Downregulated in Hu et al. and Chien et al.
HIST1H1C Garbett et al., 2008; Voineagu and
Eapen, 2013
Upregulated
HIST1H2BD Garbett et al., 2008; Voineagu and
Eapen, 2013
Upregulated
HIST1H3H Nishimura et al., 2007 Chow et al., 2012 Upregulated in Chow et al. Downregulated in
Nishimura et al.
HLA-DQA1 Gregg et al., 2008; Stamova
et al., 2011
Downregulated
HSPB1 Garbett et al., 2008; Ginsberg et al.,
2012
Upregulated
IFITM2 Garbett et al., 2008; Voineagu and
Eapen, 2013
Upregulated
IFITM3 Garbett et al., 2008; Voineagu and
Eapen, 2013
Upregulated
IGF2BP1 Ivanov et al., 2015 Walker et al., 2013 Upregulated in Walker et al. Downregulated in
Ivanov et al.
IGHA1 Gregg et al., 2008; Chien et al.,
2013
Upregulated
IGHG1 Hu et al., 2006; Gregg et al.,
2008; Chien et al., 2013
Upregulated in Chien et al. and Gregg et al.
Downregulated in Hu et al.
IL2RA Chien et al., 2013 Walker et al., 2013 Upregulated
IL2RB Gregg et al., 2008; Enstrom
et al., 2009
Upregulated
ITGB2 Gregg et al., 2008; Enstrom
et al., 2009
Upregulated
KIF1B Hu et al., 2006; Talebizadeh
et al., 2014
Garbett et al., 2008 Upregulated in Garbett et al. and Talebizadeh
et al. Downregulated in Hu et al.
KIR3DL2 Gregg et al., 2008; Enstrom
et al., 2009
Upregulated
KSP37 Gregg et al., 2008; Enstrom
et al., 2009
Upregulated
LAMP2 Chow et al., 2012 Walker et al., 2013 Downregulated
LRP6 Chien et al., 2013; Talebizadeh
et al., 2014
Downregulated
MeCP2 Kuwano et al., 2011 James et al., 2014; Zhubi et al., 2014** Upregulated in Kuwano et al. and Zhubi et al.
Downregulated in James et al.
MIA Nishimura et al., 2007 Walker et al., 2013 Upregulated in Nishimura et al. Downregulated
in Walker et al. (Colon)
MKNK2 Garbett et al., 2008; Voineagu and
Eapen, 2013
Upregulated
MSI2 Garbett et al., 2008; Voineagu and
Eapen, 2013
Upregulated
(Continued)
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TABLE 2 | Continued
Gene
symbol
Blood/LCL study Brain study Intestinal biopsy study Expression change in ASD
MSN Garbett et al., 2008; Voineagu and
Eapen, 2013
Upregulated
NDUFA2 Ginsberg et al., 2012; Anitha et al.,
2012
Downregulated
NDUFB3 Ginsberg et al., 2012; Anitha et al.,
2012
Downregulated
NDUFB5 Talebizadeh et al., 2014 Anitha et al., 2012 Upregulated in Talebizadeh et al.,
Downregulated in Anitha et al.
NEURL3 Kong et al., 2013; Chien et al.,
2013
Upregulated in Chien et al. Downregulated in
Kong et al.
NKG7 Gregg et al., 2008; Enstrom
et al., 2009
Upregulated
NP Garbett et al., 2008; Voineagu and
Eapen, 2013
Upregulated
P2RX5 Hu et al., 2006; Chien et al.,
2013
Upregulated
P4HA1 Garbett et al., 2008; Voineagu and
Eapen, 2013
Upregulated
PALLD Garbett et al., 2008; Voineagu and
Eapen, 2013
Upregulated
PAM Gregg et al., 2008; Enstrom
et al., 2009
Upregulated
PARP9 Glatt et al., 2012 Garbett et al., 2008 Upregulated in Garbett et al. Downregulated in
Glatt et al.
PIR Garbett et al., 2008; Voineagu and
Eapen, 2013
Upregulated
PITPNC1 Hu et al., 2006; Nishimura
et al., 2007
Garbett et al., 2008; Voineagu and
Eapen, 2013
Upregulated in Nishimura et al. Garbett et al.
and Voineagu et al. Downregulated in Hu et al.
PLEKHC1 Garbett et al., 2008; Voineagu and
Eapen, 2013
Upregulated
PRF1 Gregg et al., 2008; Enstrom
et al., 2009
Upregulated
PTGDR Gregg et al., 2008; Enstrom
et al., 2009
Upregulated
PTTG1IP Garbett et al., 2008; Voineagu and
Eapen, 2013
Upregulated
PXDN Stamova et al., 2011; Chien
et al., 2013
Upregulated in Chien et al. Downregulated in
Stamova et al.
RELN Chow et al., 2012; Khan et al., 2014;
Zhubi et al., 2014
Upregulated in Khan et al. Downregulated in
Chow et al. and Zhubi et al.
RPS21 Garbett et al., 2008; Ginsberg et al.,
2012
Upregulated in Garbett et al. Downregulated in
Ginsberg et al.
S100A10 Garbett et al., 2008; Voineagu and
Eapen, 2013
Upregulated
SCARA3 Garbett et al., 2008; Voineagu and
Eapen, 2013
Upregulated
SDC2 Garbett et al., 2008; Ziats and Rennert,
2013
Upregulated
SERPINA1 Chien et al., 2013 Chow et al., 2012 Upregulated in Chow et al. Downregulated in
Chien et al.
SERPINH1 Garbett et al., 2008; Chow et al., 2012;
Ziats and Rennert, 2013
Upregulated
SERTAD1 Garbett et al., 2008; Voineagu and
Eapen, 2013
Upregulated
SFTPA2 Chow et al., 2012 Walker et al., 2013 Upregulated in Chow et al. Downregulated in
Walker et al.
(Continued)
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TABLE 2 | Continued
Gene
symbol
Blood/LCL study Brain study Intestinal biopsy study Expression change in ASD
SH2DIB/EAT2 Gregg et al., 2008; Enstrom
et al., 2009
Upregulated
SHANK3 Yasuda et al., 2011; Chana et al., 2015 Downregulated
SLC38A2 Hu et al., 2006; Kong et al.,
2013
Upregulated
SLC9A9 Talebizadeh et al., 2014 Garbett et al., 2008; Voineagu and
Eapen, 2013
Upregulated
SPON2 Gregg et al., 2008; Enstrom
et al., 2009
Upregulated
STOM Glatt et al., 2012 Garbett et al., 2008; Ziats and Rennert,
2013
Upregulated in Garbett et al. Downregulated in
Glatt et al. and Ziats et al.
SYCE1 Kong et al., 2013 Chow et al., 2012 Downregulated
TAGLN2 Garbett et al., 2008; Voineagu and
Eapen, 2013
Upregulated
TAP1 Glatt et al., 2012 Garbett et al., 2008; Voineagu and
Eapen, 2013
Upregulated in Garbett et al. Downregulated in
Glatt et al.
TBX21 Gregg et al., 2008; Enstrom
et al., 2009
Upregulated
TET1 James et al., 2014; Zhubi et al., 2014 Upregulated
TIMP1 Garbett et al., 2008; Voineagu and
Eapen, 2013
Upregulated
TMBIM1 Garbett et al., 2008; Voineagu and
Eapen, 2013
Upregulated
TMEM40 Kong et al., 2013; Ivanov et al.,
2015
Downregulated
TNFRSF19 Chien et al., 2013 Chow et al., 2012 Downregulated
TNPO1 Garbett et al., 2008; Voineagu and
Eapen, 2013
Upregulated
UBD Chien et al., 2013 Walker et al., 2013 Upregulated
WWTR1 Chien et al., 2013 Garbett et al., 2008 Upregulated in Garbett et al., Downregulated in
Chien et al.
YAP1 Garbett et al., 2008; Voineagu and
Eapen, 2013
Upregulated
ZFP36L1 Garbett et al., 2008; Voineagu and
Eapen, 2013
Upregulated
**James et al. (2014). looked at MeCP2 binding to the EN-2 promoter, while Zhubi et al. (2014) looked at MeCP2 binding to the GAD1 & RELN promoters.
contrasted between young children diagnosed with ASD and
control groups, and 736 genes, which contrasted between adults
diagnosed with ASD and control groups. Ginsberg et al. analyzed
cerebellar and BA19 (Brodmann Area 19, occipital) brain tissues
from 9 control and 9 autism patients (Ginsberg et al., 2012).
After correcting for the region of the brain, they discovered 876
unique, annotated genes expressed differently between autistic
and control brains. This was a false discovery rate of five percent.
Anitha et al. compared the expression of 84 electron transport
chain genes belonging to the 5 complexes in the post-mortem
brains of 8 autism patients and 10 controls. They found that 11
genes of Complex I, 5 genes each of Complex III and Complex
IV, and 7 genes of Complex V (28 genes in total) showed brain
region-specific reduced expression in autism (Anitha et al., 2012).
Voineagu et al. profiled post-mortem samples of the superior
temporal gyrus, prefrontal cortex, and cerebellar vermis regions
from 19 autism and 17 control cases (Voineagu and Eapen,
2013). They identified 444 genes, which showed significant
expression changes in autism cortex samples as compared to
the controls, while only 2 genes were differentially expressed in
the cerebellum. Ziats et al. re-analyzed a large transcriptomic
study in the developing brain that was done by (Kang et al.,
2011; Ziats and Rennert, 2013). The study performed genome-
wide microarray analysis on postmortem human brain tissues
from 16 brain regions spanning preconception to adulthood,
specifically looking to identify sex-biased gene expression in the
developing brain. Thirty-seven female, and 123 male genes were
found to be differentially expressed by sex, brain region, and
developmental time point. Khan et al. analyzed altered thyroid
hormone-dependent brain gene expression by studying various
brain regions from 10 ASD and 11 control cases (Khan et al.,
2014). They found 14 genes that were differentially expressed
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based on sex-specific brain area. For example, expression of the
DIO2 gene, a gene involved in thyroid hormone activation, was
increased in the putamen (p < 0.05) and there was a trend
toward increase in cingulated gyrus (p = 0.08) of the female
ASD cases, while expression of the Cirbp gene, a gene responsible
for stabilizing transcripts of genes involved in cell survival, was
decreased (p < 0.05) in the putamen of ASD male cases only.
James et al. compared 1 sq cm blocks of cerebellar cortex from 13
individuals with ASD and 13 controls (James et al., 2014). They
observed a significant increase in both 5-mC and 5-hmC in the
cerebellum of individuals with ASD relative to control samples.
DNMT3A, DNMT3B, TET1, TET3, which are all genes related
to methylation and 8-oxo-deoxyguanosine (8-oxo-dG) (a major
product of DNA oxidation) expression levels were significantly
increased in the cerebellum of individuals with ASD relative to
control samples. They also found that within the EN-2 promoter
sequence there was a statistically significant positive association
between 5-hmC (a gene important in epigenetics) and EN-2 gene
expression. Additionally an association between 5-hmC and EN-
2 gene expression in the 5′ promoter CpG Island was found in
people diagnosedwith ASD but not in controls. Studies ofMeCP2
(a chromosomal protein that binds to methylated DNA) binding
in the EN-2 promoter demonstrated a significant decrease in
repressive MeCP2 binding to the identical 5′ promoter region
that contained increased levels of 5-hmC in individuals with
ASD relative to control samples. Zhubi et al. also compared
blocks of cerebellar cortex from 10 individuals with ASD and
10 control samples. They found a one and a half to two time
increase in binding of MeCP2 to GAD1 and RELN promoters
in the cerebellum of individuals diagnosed with autism when
contrasted to controls. RELN plays a role in layering of neurons
in the cerebral cortex and cerebellum. They detected that levels
of 5-hmC were significantly enriched at GAD1 and RELN
promoters in individuals with ASD. The methylation changes
they found lead to a remarkable increase in the amounts of 5-
hmC relative to 5-mC. The 5-hmC/5-mC ratio at the GAD1
promoter is 5.5 in people diagnosed with ASD and only 1.2 in
controls. Similar to James et al. (2014), they also found TET1
mRNA levels to be increased in the cerebella of individuals with
ASD (Zhubi et al., 2014). Chana et al. (2015) compared data from
brain tissue from 30 controls and 27 individuals diagnosed with
ASD. They found that expression of mGluR5 was decreased in
ASD when compared to controls. This gene has been found to be
associated with the forming of synapses, activation of microglia,
and other processes.
Immune System
One study demonstrated findings in post-mortem brain tissue
that were specific to the immune system. Considering the
extensive literature analyzing the relationship between the
immune system and ASD (Gesundheit et al., 2013), this demands
further attention. Garbett et al. analyzed frozen samples of
superior temporal gyrus from 6 subjects with ASD and 6
controls (Garbett et al., 2008). Based on four parameters, they
identified 152 differentially expressed gene products, and of
these, 130 demonstrated increased expression while 22 showed
decreased levels in the brains of individuals with ASD. Seventy-
two annotated differentially expressed transcripts were either
cytokine responsive transcripts or transcripts related to the
immune system. Additionally, they noticed decreased transcript
levels for a number of genes involved in outgrowth and neuronal
differentiation. They used Gene Set Enrichment Analysis, which
marks functional pathways in which gene expression changes
are grouped together. This enabled the identification of 31 gene
sets that were differentially expressed between individuals with
autism and control samples. Of the 31, 19 genes were involved in
immune system function.
PERIPHERAL BLOOD GENE EXPRESSION
STUDIES
The second and most common source used in gene expression
studies for autism was lymphoblastoid cell lines (LCLs). There is
an apparent discrepancy between neuroanatomical and cellular
abnormalities observed for autism at younger ages andmolecular
pathologies at more advanced ages. Hu et al. analyzed LCLs
derived from lymphocytes of 3 pairs of monozygotic twins
that were discordant with respect to clinical diagnosis of
ASD (Hu et al., 2006). Twelve hundred genes were identified
as significant with a false discovery rate of 26%, 25 genes
were found to be up-regulated at least 1.5-fold in the more
severely affected twin relative to the other twin (log2 (ratio)
= 0.58) and 19 genes were down-regulated by at least 1.5-
fold. Of these, eight of the 26 genes match genes connected
to neurological function, development, or disease. In 2009,
Hu et al. conducted microarray analysis on 116 LCLs from
individuals with idiopathic autism who were separated into
three phenotypic subcategories according to severity scores from
the ADI-R questionnaire and age-matched, typically developing
controls. They identified 530 significantly differentially expressed
genes that distinguished controls from all samples with ASD.
Hu et al. analyzed gene expression profiling and how it
differentiates ASD from controls and phenotypic variants of ASD
(Hu et al., 2009). Microarray analyses were conducted on 116
LCLs from individuals with idiopathic ASD who were separated
into three phenotypic subgroups according to severity scores
from the ADI-R questionnaire and age-matched, non-autistic
controls. Five hundred and thirty significantly differentially
expressed genes were found that distinguished the samples
of ASD from controls. They also identified 123 significant
genes from 4-class significance analysis of microarrays (SAM)
analysis of data from gene expression from severe, mild,
and savant subgroups and the non-autistic control groups.
When the pathways of the overlapping genes were analyzed
between the severe language and mild autism subgroups,
a network of genes that affect common functional targets,
such as synaptic transmission, neurogenesis, neurulation, long-
term potentiation (learning), protein ubiquitination, and brain
function was revealed. Additionally, 15 significant differentially
expressed genes that regulate circadian rhythm were found,
unique to the most severely affected ASD subgroup. Differential
expression of these genes was observed only in the samples
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from severely language-impaired individuals (L subgroup), with
each individual showing altered expression of multiple (but not
all 15) genes. Emanuele et al. investigated increased dopamine
DRD4 receptor mRNA expression in lymphocytes of individuals
diagnosed with autism and musicians in order to explore the
music-autism connection. The DRD4 receptor is known to be
responsible for neuronal signaling in the mesolimbic system of
the brain. They studied 20 ASD patients, 19 professional adult
musicians, and 19 gender and age matched control individuals
who were not interested in playing or listening to music. Analysis
of variance (ANOVA) demonstrated significant differences in
DRD4 mRNA expression between the groups (P = 0.008).
Post-hoc analysis highlighted significant differences between the
control group and both musicians (P < 0.05) and individuals
diagnosed with ASD (P < 0.05) (Emanuele et al., 2010). Yasuda
et al. measured mRNA expression levels in lymphoblastoid cells
from 35 subjects with ASD and 35 controls. They found that in
individuals diagnosed with autism, B-actin normalized NLGN3
expression levels or TATA-binding protein were decreased by
35 or 26% respectively. They also found that gene expression
levels of the SHANK3 gene, a gene that codes for a major
scaffold postsynaptic density protein, regulated by B-actin or
TATA binding protein were also decreased in individuals with
autism by 39 or 40% respectively (Yasuda et al., 2011).
Stamova et al. looked for correlations between gene expression
and mercury level in blood of boys with and without ASD.
They collected whole blood from 33 boys with ASD and 51
age-matched typically developed (TD) control boys. There was
no significant difference in Hg levels between the ASD and
TD groups. They found 11 genes whose expression correlated
inversely with mercury levels in boys diagnosed with autism
compared to typically developing children. One limitation of this
study was that samples collected from children ages 2–5 do not
consider the possible direct role of mercury as a causal factor for
autism, which likely starts in utero or shortly after birth (Stamova
et al., 2011).
Tian et al. looked for correlations of gene expression with
blood lead levels in children diagnosed with autism contrasted
to typically developed controls. They looked at 37 children with
ASD, and 15 TD controls. There was no significant difference
in blood lead levels. Forty-eight probe sets represent 31 genes,
whose expression correlated with lead levels in each group,
and the partial correlation coefficients were statistically different
between the groups; most of the genes are negatively correlated
with blood lead levels in typically developed children and
positively correlated with blood lead levels in children diagnosed
with autism. The conclusion of their study, however was that
lead most likely does not explain the increasing incidence in ASD
(Tian et al., 2011).
Alter et al. looked at ASD and changes related to paternal
age in overall levels of gene expression regulation. They
performed gene expression microarrays on RNA from peripheral
blood lymphocytes of 82 children with ASD and 64 controls
where parental age was similar between the 2 groups. They
then performed a secondary analysis by analyzing paternal
age difference as a risk factor for ASD and whether it was
associated with variance. They found that the distribution of gene
expression levels on microarrays from individuals with autism
had a decreased variance when compared to microarrays from
controls (p = 0.006). They also found that in controls, but
not in children with ASD, overall variance in gene expression
was found to be significantly and negatively associated with
the age of the father (p = 0.03), so as predicted, the overall
variance was the same in children of fathers who were older and
children with ASD with fathers of any age. In the comparison
of children with ASD to children with fathers of a younger
age, there were 2093 genes that were significantly downregulated
by at least 1.1-fold, and only 641 that were upregulated. In
the blood of children with fathers who were older compared
to the children with younger paternal age, there were 1476
downregulated and 764 upregulated genes. There were 593 genes
that were downregulated in both children with ASD and children
of with older fathers (p< 0.000001) and 145 genes that were
upregulated in both comparisons (Alter et al., 2011).
Chien et al. looked at increased gene expression of FOXP1
by comparing LCL between 16 males diagnosed with ASD and
16 male controls. FOXP1 is a transcriptional repressor. A total
of 252 differentially expressed probe sets corresponding to 202
genes were detected between the 2 groups, including 89 up-
and 113 down-regulated genes in the group diagnosed with
autism. Real-time quantitative polymerase chain reaction (RT-
qPCR) verified significant elevation (1.89 ± 2.64, P = 0.005)
of the FOXP1 gene transcript of LCL in a sample of 83 male
patients, compared with 83 male controls. Using three platforms,
they found several immune-related pathways showing significant
differences between the ASD patients and controls (Chien et al.,
2013).
Prandini et al. analyzed RBFOX1 gene expression in LCL
of Italian discordant ASDs sib-pairs totaling 36 children
and adolescents. Their data showed however, that RBFOX1
normalized mean values were not significantly different between
controls and those diagnosed with ASD, they suggested a possible
cause for this might have been due more subtle transcription
level differences in RBFOX1 gene expression in LCL than in brain
samples (Prandini et al., 2014).
Talebizadeh et al. performed a pilot study and looked at exon-
level expression profiling and alternative splicing in ASD using
LCL. They found 57 genes that were differentially expressed at
the exon level between ASD and control samples. They also
found differential splice variants of the gene CYFIP1 (which has
2 protein-coding transcripts in the literature), exon array analysis
demonstrated a higher expression for the probe sets which binds
to exon 16 in variant 1 (encoding a long form) in subjects with
ASD vs. controls. DNA sequencing following RT-PCR for variant
1 also detected a product missing exon 16 inducing a premature
stop codon, and qRT-PCR showed a higher expression of variant
1 in ASD compared with control samples. RT-PCR reactions
were run for TRAP150 and ZMYM6 and DNA sequencing of the
amplified products supported the fact that these exons undergo
alternative splicing and enabled the indication of previously
unreported alternative splicing isoforms for these two genes.
These new variants included one isoform of TRAP150 (missing
exon 4 resulting in an in-frame loss of 301 amino acid residues)
and five alternatively spliced ZMYM6 variants that are labeled on
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the basis of the missing exons (isoforms missing exon 2, exon
4, exons 2&4, exons 2&5, and exons 2, 4, &5). ZMYM6 variants
missing exon 2, the location of the start codon, most likely do not
code for proteins and the exclusion of only exon 4 introduces a
premature stop codon (Talebizadeh et al., 2014).
Immune System-Background
The role of the immune system in ASD is an active area
of research. Evidence of an immune role in at least a subset
of children diagnosed with ASD can be divided into brain
antibodies, serum cytokines, family history and immunogenetics
(Gesundheit et al., 2013).
Immune System-Gene Expression Studies
Gregg et al. subdivided the children into three groups based on
various clinical criteria. Their sample size included 49 children on
the autism spectrum and 12 controls. Unpaired t-tests detected
a number of genes that were regulated more than 1.5-fold for
autism vs. general population (n = 55 genes), for history of
early onset vs. general population (n = 140 genes), and for
developmental regression vs. general population (n = 20 genes).
The three gene lists from the analysis were used to identify
a small group of 11 genes that are shared between the three
groups. These genes were all expressed in natural killer cells and
many belonged to the KEGG natural killer cytotoxicity pathway.
Database for Annotation, Visualization and Integrated Discovery
(DAVID) and Ingenuity Pathway Analysis were used to analyze
pathways, and notable pathway overlaps included natural killer
cell signaling in all three comparisons, IL-2 signaling and
serotonin receptor and dopamine receptor signaling in autism
vs. general population and early onset vs. general population, and
retinol and methionine metabolism in the early onset vs. general
population analysis (Gregg et al., 2008).
Enstrom et al. analyzed peripheral blood from 35 children
with ASD and 11 age and gender matched controls. They
discovered that a total of 626 probes showed differential gene
expression between the two groups (82 significantly higher and
544 significantly lower in the ASD group). The 82 upregulated
probes in ASD correlated to 59 known genes, most of which
have been connected to leucocyte function, more specifically the
function of natural killer cells. Using microarray analysis, their
studies demonstrated that 12 gene probes, corresponding to 11
different genes were differentially expressed in early onset and
regressive types of ASD when compared with the control group.
Flow cytometric analysis of natural killer cells demonstrated
increased production of granzyme B, perforin, and interferon
gamma (IFNγ) under resting conditions in children diagnosed
with ASD (Enstrom et al., 2009).
Kuwano et al. looked at ASD-associated gene expression in
peripheral leucocytes that were often noticed between subjects
with ASD, and healthy mothers of children with ASD. They
used DNA microarray to perform gene expression profiling in
peripheral blood on 21 individuals from 4 groups: young adults
with ASD, age and gender matched controls, mothers having
children with ASD (asdMO), and age matched controls having
healthy children. They found 19 genes that were significantly
differentially expressed (18 up and 1 down-regulated) when
comparing the ASD to the control group, and 57 genes that
were differentially expressed between the asdMO group and
the asdMO control group (17 up-regulated and 40 down-
regulated genes fold change >2.0). Three genes overlapped and
were dysregulated in both individuals diagnosed with ASD and
in asdMO. An ASD-associated gene expression pattern was
often observed in both asdMO and individuals with ASD even
though they had no symptoms above clinical threshold of ASD
(expression of the 19 and 57 genes was changed in a parallel
direction; Kuwano et al., 2011).
Glatt et al. identified 60 infants and toddlers at risk for
ASDs, 34 at risk for language delay, 17 at risk for global
developmental delay, and 68 typically developing children. One
hundred and fifty four probes showed significant dysregulation in
ASD, and a log 2-fold change. The most accurate support vector
machine utilized the magnitude of the expression of 48 probes
to classify 71% of ASD and control subjects across 10 subsets of
discovery sample into their appropriate diagnostic categories. Of
30 individuals diagnosed with ASD, 27 were correctly classified
by this support vector machine as having ASD, 23/34 control
subjects were correctly classified as controls. The list of 48 probes
making up the best support vector machine classifier of ASDs
was most significantly enhanced with genes related to immune
responses, genes of the hemoglobin complex, and genes with
guanine- or guanylate-binding affinity (Glatt et al., 2012).
Kong et al. performed a genome-wide expression profile
of the blood from 20 proband-unaffected sibling pairs, and
18 unrelated controls. One hundred and eighty nine probe
sets that represented 163 unique genes (including 2 previously
reported ASD candidate genes) were significantly changed
between probands and siblings—84 probands were up-regulated
compared to unaffected siblings (Kong et al., 2013).
Segura et al. looked at neurotrophin blood-based gene
expression and social cognition analysis by obtaining whole
blood from 21 adults and adolescents diagnosed as ASD, as well
as from 10 controls. Social cognition abilities of subjects with
ASD and controls were determined according to three Theory of
Mind tests (RME, Faux pas test, The Happé stories). They found
that NT3 and NT4 mRNA expression in the whole blood was
significantly lower in ASD patients compared to healthy controls
(P < 0.05). They also found that P75NTR mRNA expression
was significantly higher in ASD patients than in controls. The
ASD group received lower scores in three Theory of Mind
tasks compared to the control group, which indicates that social
cognition impairments in association with the ASD phenotype,
yet no correlations were observed between neurotrophins and
their receptors expressions and measures of Theory of Mind
(Segura et al., 2015).
GI AND ASD BACKGROUND
Gastrointestinal (GI) symptoms are common in children with
ASD compared with typically developing children and those with
other developmental delays. Some controversial studies suggest
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that as many as 70% of children with ASD exhibit chronic
GI-related symptoms (Walker et al., 2013).
GASTROINTESTINAL TISSUE GENE
EXPRESSION STUDIES
Williams et al. looked at impaired carbohydrate digestion and
transport and mucosal dysbiosis in the intestines of children
diagnosed with ASD and gastrointestinal disorders. They found
that the levels of three brush border disaccharidases (sucrase
isomaltase [SI], maltase glucoamylase [MGAM], and lactase
[LCT]) were all significantly decreased in children with ASD and
GI complaints (ASD-GI). Within the ASD-GI group, 86.7, 80,
and 80% of children had lower transcript levels in SI, MGAM,
and LCT respectively. Almost all (14/15, or 93.3%) ASD-GI
children had deficiencies in at least one disaccharidase enzyme;
80% had deficiencies in 2 or more enzymes; and 73.3% had
deficiencies in all three enzymes. Real-time polymerase chain
reaction (RT-PCR) revealed a significant decrease in 2 hexose
transporters: ileal SGLT1 mRNA and GLUT2 mRNA in ASD-
GI children. For SGLT1, 73.3% of ASD-GI children had deficient
transcript levels, and 73.3% of ASD-GI children had deficient
GLUT2 transcript levels, relative to control-GI children. In total,
93.3% (14/15) of ASD-GI children had mRNA deficiencies in at
least one of the five genes involved in carbohydrate digestion or
transport; 66.7% (10/15) had mRNA deficiencies in all five genes
(Williams et al., 2011).
Similarly, Walker et al. looked at subjects including children
with ASD and three typically developing groups including (1)
children who underwent diagnostic ileocolonoscopy for chronic
GI symptoms in which no histopathology; (2) children with
Crohn’s disease (3) and children with ulcerative colitis. Pairwise
analysis between the ileal mucosa from ASD-GI and non-
inflamed control samples resulted in 1409 differentially expressed
transcripts unique to the ASD-GI samples. Pairwise analysis
between inflamed colonic mucosa from ASD-GI children and
non-inflamed control samples resulted in 1189 differentially
expressed transcripts unique to ASD-GI samples. The overlap
between the 2 sets (ileum and colon) resulted in 178 transcripts
that were exclusively differentially expressed in both ileal and
colonic tissues form the ASDGI population. When these 178
transcripts were analyzed using Ingenuity Pathway Analysis
software, three of the top associated biological functions
were inflammatory disease, endocrine system development
and function, and digestive system development and function
(Walker et al., 2013).
ADULT OLFACTORY STEM CELL GENE
EXPRESSION STUDIES
Féron et al. used adult nasal olfactory stem cells from nine adults
with severe ASD and low developmental disabilities (DSM-5),
plus two adults with mild ASD and no or mild cognitive abilities
(Asperger syndrome or high functioning ASD) paired with 11
age and gender matched controls. Gene microarray analysis
highlighted 156 genes that were differentially expressed in at least
one ASD patient, of which 31 were dysregulated in more than
33% of the cohort (9 out of the 156 genes have been previously
associated with ASD). They found that MOCOS, an enzyme
involved in purine metabolism, is downregulated in most ASD
individuals (8/11), compared to controls (Féron et al., 2016).
HAIR FOLLICLE GENE EXPRESSION
STUDIES
Maekawa et al. utilized scalp hair follicles as a source of
biomarker genes and found that the gene CNTNAP2 showed
significantly decreased expression in samples from subjects with
ASD compared with control follicles (Maekawa et al., 2015).
GENE EXPRESSION ANALYSIS:
COMORBIDITIES
A few of the gene expression studies looked at people diagnosed
with ASD and comorbidities.
ASD and Fragile X/Dup 15q
Nishimura et al. performed genome-wide expression profiling
of LCL in order to distinguish different forms of ASD and to
reveal shared pathways. Individuals with ASD both with and
without FMR1-FM or dup (15q) were compared to TD male
controls. The combination of ANOVA, SAM and RankProd,
isolated 120 genes in ASD with FMR1-FM, and 80 genes in
ASD dup (15q), 68 genes were found to be dysregulated in
both ASD with FMR1-FM and dup (15q) (so 52 genes were
selectively dysregulated only in ASD with FMR1-FM, and 12
genes were selectively dysregulated only in ASD with dup (15q).
They also found a potential molecular connection between
FMR1-FM and dup (15q), the cytoplasmic FMR1 interaction
protein 1 (CYFIP1), which was up-regulated in dup (15q)
patients. Expression of JAKMIP1 and GPR155 was significantly
dysregulated in the 27 males with ASD when compared with
their siblings without ASD. JAKMIP1 is a gene known to be
related to microtubule transport. Genes related to chaperone
and protein folding were enriched in the 52 genes selectively
dysregulated in ASD with FMR1-FM; genes related to RNA
binding and mRNA metabolism were also enriched in this set
(this is consistent with FMRP protein’s function as an RNA
binding protein important in regulatory translation) (Nishimura
et al., 2007).
ASD and ADHD
Taurines et al. looked at altered mRNA expression of
monoaminergic specific genes in the blood of children
with ADHD and ASD. They found a significant group
difference with decreased DRD5- level in ASD patients
when compared with controls and to patients diagnosed with
ADHD. Post-hoc analyses demonstrated reduced DRD4-levels
in the group of both ADHD patients and ASD patients
when compared with healthy controls (Taurines et al.,
2011).
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GENE EXPRESSION IN ASD-SUMMARY
(TABLE 2)
Sample Source Types
When the gene expression studies are viewed together
independent of source type, over 100 genes are found in
more than one study. Interestingly, whether the gene is up-
regulated or down-regulated is independent of the source of the
gene sampled and can even vary within the same source type
in different studies. For example, the gene NDUFB5 was found
to be upregulated in LCL derived cell line RNA’s (Talebizadeh
et al., 2014), but downregulated in three different regions of post-
mortem brain tissue (Anitha et al., 2012). The gene NEURL3 was
up-regulated in peripheral blood in a study conducted by Chien
et al. (2013), but down-regulated in peripheral blood in a study
conducted by Kong et al. (2013). However, most genes that were
up or down-regulated followed the same pattern in different
studies across sample source types.
Pathways (Table 3)
One of the aims of gene expression studies is to look for
multiple genes in the same pathway. This should provide some
clues to the underlying mechanism of the disease. From the
studies surveyed, five pathways were found three times across
different studies, and eight pathways were found twice. The
pathways that were found three times included: cell cycle, cell
death, GI disease, immune function, and neurogenesis. All of
these areas are already areas of extensive research in ASD
and therefore, they are not-surprising. The pathways that were
found twice were: alternative splicing, arrhythmogenic right
ventricular cardiomyopathy, cellular assembly and organization,
cell-to-cell signaling and interaction, gap junction, inflammation,
small molecule biochemistry, and ubiquitinmediated proteolysis.
While inflammation and cell signaling are already areas of
research for ASD, the potential relationship between the other
pathways and ASD deserves further consideration. Amore recent
paper by Ivanov et al. (2015) highlights a number of other
pathways and their importance in understanding the function
of genes including the Wnt pathway and the calcium pathway,
which is involved in the development of the nervous system and
deserves further investigation regarding its potential role in ASD.
Similarly, Wen et al. (2016) found the calcium signaling pathway
to be a very active pathway in ASD. The precise role of calcium
signaling in ASD and its potential relationship to other common
metabolic disturbances in ASD demands further research.
Specific Genes/Pathways Already
Implicated in ASD or in Processes Relevant
to ASD
There are numerous examples of specific genes that have been
shown to be altered between ASD and control samples. All have
been shown to be directly related to important processes that
when reduced or altered, can be connected to ASD. These genes
can be roughly subdivided into genes related to the brain and
genes related to the immune system.
Brain Related Genes
Hu et al. found the protein ASS to be upregulated in the
autism samples. ASS controls the rate-limiting step involved in
nitric oxide (NO) production via regeneration of arginine from
citrulline, a by-product of the nitric oxide synthetase (NOS)
reaction. Since NO is a important signaling molecule in the brain
and has been implicated in several disorders, including ASD, thus
the increased expression of ASSmay be potentially relevant to the
ASD phenotype (Hu et al., 2006).
Based on the findings of Nishimura et al., since CYFIP1,
which was shown to be upregulated in dup (15q) patients is
known to counteract FMRP, they reason that the induction of
CYFIP1 in dup (15q) might elucidate some of the significant
overlap between ASD with FMR1-FM and with dup (15q). They
also found that JAKMIP1 was significantly induced in ASD
with FMR1-FM and had a positive trend in ASD with dup
(15q), suggesting that JAKMIP1 could represent a commonly
dysregulated pathway. This gene is a particularly biologically
important candidate, given its putative role in GABAB receptor
expression and microtubule networks (Nishimura et al., 2007).
Since Taurines et al. found reduced expression in ASD
probands of DRD5 which is expressed in the hippocampus
associated areas and is thought to be important in the induction
of long term potentiation related to novel events, it can be
suggested that the reduced expression could give insight into
the fact that probands have less expression of an important
hippocampal gene (Taurines et al., 2011).
Kuwano et al. found that mRNA levels of ITGA2B encoding
glycoprotein (GP) αIIβwere upregulated both in individuals with
ASD and in asdMO; GPαIIβ forms αIIbβ3 integrin with ITGB3,
an ASD-susceptible gene. Since αIIbβ3 integrin has an critical
role in cell morphology, including synapse maturation, the
increased expression of ITGA2B mRNA might change cellular
morphology of peripheral cells in mothers having children with
ASD as well as subjects with ASD (Kuwano et al., 2011).
Chow et al. showed that the A2A receptor-signaling pathway
was the top dysregulated pathway in the young autistic brain.
Adenosine receptors are crucial for both brain development
and function including the regulation of neuronal stem cell
proliferation, synaptic plasticity, motor function, cognition and
emotion-related behaviors (Chow et al., 2012).
Voineagu et al. identified that A2BP1/FOX1, a neural and
muscle specific alternative splicing regulator (and the only
splicing factor previously implicated in ASD) was down-
regulated in several individuals with ASD (Voineagu and Eapen,
2013).
The reports of James et al. showed that elevated 5-hmC in
the EN-2 promoter is correlated with a significant decrease
in repressive MeCP2 and histone H3K27me3 which appear to
override 5-mC hypermethylation. These epigenetic changes are
thought to loosen enhancer region chromatin which would
facilitate enhancer binding and promote sustained upregulation
of EN-2 expression. Since perinatal EN-2 downregulation is
crucial for normal Purkinje cell differentiation and cerebellar
patterning, the consistent postnatal overexpression of EN-2
suggests that the shutting of this programmed developmental
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TABLE 3 | List of main pathways affected.
Paper Software List of main pathways affected
Alter et al., 2011 DAVID analysis Alternative splicing, splice variant, zinc-finger, phosphoprotein, zinc, metal-binding, zinc-ion
binding, dna-binding, ubiquitin mediated proteolysis, nucleus, transcription, transition metal ion
binding, chromosomal rearrangement, ubl conjugation pathway, transcription regulation, coiled
coil, regulation transcription, compositionally biased region: Ser-rich
Chien et al., 2013 DAVID analysis Long-term depression, Cytokine-cytokine receptor interaction, Vascular smooth muscle
contraction, Arrhythmogenic right ventricular cardiomyopathy (ARVC), glycerophospholipid
metabolism, allograft rejection, Jak-STAT signaling pathway, Hematopoietic cell lineage, Gap
junction, T cell receptor signaling pathway, RIG-I-like receptor signaling pathways, Ubiquitin
mediated proteolysis, Intestinal immune network for IgA production, Type II diabetes mellitus,
Leukocyte transendothelial migration, GnRH signaling pathway
EMA (Easy Microarray data Analysis) Long-term depression, Amoebiasis, Vascular smooth muscle contraction, Cytokine-cytokine
receptor interaction, Arrhythmogenic right ventricular cardiomyopathy (ARVC), Intestinal
immune network for IgA production, Endocytosis, Aldosterone-regulated sodium reabsorption,
African trypanosomiasis, Graft-vs.-host disease
GSEA Gene Set Enrichment Analysis Arrhythmogenic right ventricular cardiomyopathy ARVC, terpenoid backbone biosynthesis,
glycerophospholipid metabolism, vascular smooth muscle contraction, alpha linolenic acid
metabolism, tight junction, inositol phosphate metabolism, cytosolic dna sensing pathway,
renal cell carcinoma, cell receptor signaling pathway, chronic myeloid leukemia
Chow et al., 2012
Young autistic/control MetaCore software suite DNA damage-response, cell cycle and apoptosis-related pathways
DAVID analysis DNA damage/cell cycle, apoptosis, and immune signaling and neurogenesis and neural
development
Adult autistic/control MetaCore software suite Cell differentiation, mitogenic signaling and apoptosis genes
All autistic and control cases
independent of age
DNA-damage response, apoptosis and immune system response functions
Enstrom et al., 2009 DAVID analysis NK function, cellular proliferation, and leukocyte function
Féron et al., 2016 IPA analysis Developmental disorders, gastrointestinal diseases, purine metabolism, inflammation
Garbett et al., 2008 GSEA Gene Set Enrichment Analysis Antigen-specific immune response, inflammation, cell death, autoimmune diseases, migration,
and targeting of the immune response to specific cells
Ginsberg et al., 2012 DAVID analysis Mitochondrial oxidative phosphorylation, protein translation, synapse/neurotransmitters, vesicle
transport, brain patterning,
IPA analysis Oxidative phosphorylation
Glatt et al., 2012 DAVID analysis Genes related to immune response, genes of the hemoglobin complex, and genes with
guanine- or guanylate-binding affinity
Gregg et al., 2008 DAVID analysis Natural killer cell-mediated cytotoxicity
IPA analysis Natural killer cell signaling, IL-2 signaling, serotonin receptor and dopamine receptor signaling,
retinol and methionine metabolism
Hu et al., 2006 IPA analysis Neurological development and function, neuronal signaling, extension of neurites, myelination,
VEGF-induced release of nitric oxide, neurogenesis, survival of Purkinje cells, apoptosis of
neurons, development of septum, TNF and other cytokines
Hu et al., 2009 IPA analysis Synaptic transmission, neurogenesis, neurulation, long-term potentiation (learning), protein
ubiquitination, brain function, molecular and cellular functions, cell death, small molecule
biochemistry, free radical scavenging, cellular function and maintenance, liver toxicity, circadian
rhythm, and androgen sensitivity
Ivanov et al., 2015 KEGG pathway analysis Calcium signaling pathway, Amphetamine addiction, Leishmaniasis, GABAergic synapse,
Retrograde endocannabinoid signaling, MAPK signaling pathway, Arrhythmogenic right
ventricular cardiomyopathy (ARVC), Cholinergic synapse, GnRH signaling pathway,
Glutamatergic synapse, Serotonergic synapse, Dopaminergic synapse, Steroid biosynthesis,
Steroid biosynthesis, Wnt signaling pathway, Leukocyte transendothelial migration,
Hypertrophic cardiomyopathy (HCM), Dilated cardiomyopathy, Asthma, Influenza A,
Carbohydrate digestion and absorption and Endocrine and other factor-regulated calcium
reabsorption
Kong et al., 2013 GSEA Gene Set Enrichment Analysis Ribosome and spliceosome pathways, neuroactive ligand receptor interaction pathway,
calcium signaling pathway, and Gap junction
Kuwano et al., 2011
ASD/control group IPA analysis Cell morphology, cellular assembly and organization, nerve system development and function
asdMO/asdMO IPA analysis Cancer, RNA post-transcriptional modification, reproductive system disease, protein synthesis,
immune functions
(Continued)
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TABLE 3 | Continued
Paper Software List of main pathways affected
Mahfouz et al., 2015 DAVID analysis Synaptogenesis, regulation of apoptosis, regulation of cell death, GABAergic neurons, neuron
projection, neuron differentiation, cell morphogenesis, learning/memory, behavior, mental
retardation, epilepsy, mitochondrial function, protein translation, ubiquitination, synapse
formation and elimination, protein turnover, ion channel, neurotransmitter receptor activity, and
mitochondrial function
Nishimura et al., 2007 DAVID analysis Cell communication and signal transduction, immune response, defense response
IPA analysis Cell cycle, cellular movement, and cell-to-cell signaling and interaction
Pramparo et al., 2015 Metacore GeneGo analysis Apoptosis/Apoptotic nucleus, Immune response/Antigen presentation, Immune
response/Phagocytosis, Immune Response/TCR signaling, Translation/Translation initiation,
Inflammation/Interferon signaling, Apoptosis/Anti-Apoptosis via NF-kb, Cell
Adhesion/Leukocyte chemotaxis, Inflammation/IFN-gamma signaling
Stamova et al., 2011 IPA analysis Cellular Assembly and organization, cellular compromise, small molecule biochemistry, vitamin
and mineral metabolism, cell death, neuronal development, neuronal survival
Talebizadeh et al., 2014 DAVID analysis Protein-lipid modification
Tian et al., 2011 IPA analysis Immunological and inflammatory disease processes, cell-cell signaling, antigen presentation,
cell cycle, development and growth, proliferation, mitochondrial dysfunction pathways
Voineagu and Eapen, 2013 GO gene ontology enrichment
analysis
Synaptic function, immune and inflammatory function
Walker et al., 2013
Ileal Mucosa PCA (Principal component analysis) Gastrointestinal disease, inflammatory response, humoral immune response, tissue
morphology, digestive system development and function, O-Glycan Biosynthesis, Propanoate
Metabolism, Arginine and Proline Metabolism, and Alanine and Aspartate Metabolism
Colonic Mucosa PCA (Principal component analysis) Gastrointestinal disease, neurological disease, behavior, organ development, Atherosclerosis
Signaling, Factors Promoting Cardiogenesis in Vertebrates and Mitotic Roles of Polo-Like
Kinase
IPA analysis Inflammatory disease, endocrine system development and function and digestive system
development and function, Granzyme A Signaling, Athersclerosis Signaling, Valine, Leucine and
Isoleucine Degradation and Clathrin-mediated Endocytosis Signaling
Wen et al., 2016 KEGG Pathway Analysis MAPK signaling pathway, Calcium signaling pathway, Cell signaling, cell structure/transport,
metabolism, neural, immune, cancer, cardiac disease, metabolic disease, Cell Adhesion
Molecules, Wnt signaling pathway, mTOR signaling pathway, Focal adhesion, Regulation of
actin cytoskeleton, Ubiquitin mediated proteolysis, Long-term potentiation, Axon guidance,
and neurodegenerative diseases
Ziats and Rennert, 2013 DAVID analysis Extracellular matrix formation/glycoproteins, immune response, chromatin, and cell
cytoskeleton
window may have been missed in some individuals with ASD
because of epigenetic abnormalities (James et al., 2014).
NT3&NT4, which were down to have lower expression in
ASD patients compared to controls by Segura et al. play a crucial
role in the development of the climbing fiber system of the
cerebellar Purkinje cells (PCs), and NT3 selectively increased
their survival. PC’s are the primary efferent neurons of the
cerebellar cortex, and its potential involvement in ASD has long
been proposed. Neuropathological studies have shown significant
reductions in the number and size of PCs in ASD post-mortem
brain. Therefore, they hypothesize that reduced NT3 levels in the
periphery in ASD patients might reflect altered expression in the
CNS which may be associated with a loss of PC that result in
altered cerebellar cortical efferent signals (Segura et al., 2015).
CNTNAP2, which encodes the contactin associated protein-
like 2, which was found have significantly decreased gene
expression in Maekawa et al. is one of the most intense
ASD susceptibility genes with supporting evidence from several
independent studies (Peñagarikano and Geschwind, 2012).
CNTNAP2, a neurexin family protein that acts as a neuronal
adhesionmolecule and receptor. It was found to be a direct neural
target of the human FOXP2 protein, and mutations of FOXP2
and CNTNAP2 were linked to language and speech disorders
in ASD (Maekawa et al., 2015). The FOXP1 gene, which was
found to be elevated in ASD subjects according to Chien et al.
functions as a transcription repressor, forms a heterodimer with
FOXP2, and is co-expressed with FOXP2 in numerous brain
regions, suggesting close functional cooperation between the two
proteins. FOXP1 is extensively expressed in the developing and
mature brain and has been suggested to be important for brain
development and function. Based on their data, it indicates that
associations among FOXP1, FOXP2, and CNTNAP2 genes may
play an important role underlying the pathogenesis of syndromic
and non-syndromic ASD. They inferred that increased FOXP1
gene expression may lead to increased FOXP2 gene expression
through a feedback mechanism, which may in turn reduce the
gene expression of CNTNAP2 in patients with ASD (Chien et al.,
2013).
Feron et al. found MOCOS to be downregulated in most
ASD individuals as compared to controls. In vivo and in vitro
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engineered models indicate that altered expression of MOCOS
results in neurotransmission and synaptic defects. MOCOS
expression also induces increased oxidative stress sensitivity.
Metabolic disorders of purine metabolism have been shown to
affect the nervous system and are able to induce autistic features
(Féron et al., 2016).
Immune Related Genes
Gregg et al. found that SH2D1B/EAT2, one of the 11 differentially
expressed genes they found to overlap in all 3 groups (AU vs.
GP, A-E vs. GP, and A-R vs. GP), is mostly expressed in natural
killer cells as well as macrophages, B cells, and dendritic cells,
and has been theorized to suppress natural killer cell activity
through the binding of protein tyrosine phosphatases, inhibitory
kinases, or ubiquitin ligases. Abnormalities in RUNX3 (one of
the 55 differentially expressed genes in AU vs. GP) function
in leukocytes and is associated with sudden development of
colitis and gastric mucosal hyperplasia and might be relevant to
ASD since a small group of children with ASD appear to have
gastrointestinal abnormalities (Gregg et al., 2008).
The findings of Enstrom et al. suggest possible dysfunction of
natural killer cells in children with ASD, and the data suggests
that circulating natural killer cells in ASD are persistently
activated rather than quiescent (Enstrom et al., 2009).
Reduced expression of NLGN3 and SHANK3 genes in
lymphoblasts of individuals with ASD is consistent with previous
reports indicating that mutations of these genes cause reduced
expression or loss of function of the protein. Yasuda et al. found
that both these genes were found to be decreased in individuals
in ASD (Yasuda et al., 2011).
One of the 48 biomarkers in the optimized support vector
machine classifier by Glatt et al. IF116, was previously found to
be dysregulated in the postmortem temporal cortex of subjects
with ASD (Garbett et al., 2008; Glatt et al., 2012).
GENERAL LIMITATIONS IN RNA-GENE
EXPRESSION STUDIES: A CRITICAL
APPRAISAL OF THE DATA
Variance
One limitation of mRNA gene expression studies is variance.
While gene specific approaches are helpful, they may ignore
changes known as variance occurring at the global level of
gene expression regulation. Global levels of gene expression
regulation are crucial for understanding the underlying basis
of diseases such as ASD where multiple systems are affected.
For example, the associated increased risk of ASD in children
of older fathers could be mediated by changes in global levels
of gene expression regulation, or by paternally transmitted
age related factors that are linked to changes in the global
regulation of gene expression (Alter et al., 2011). Thus,
it is possible that a common mediator, a change at the
global level of gene expression regulation, could offer an all-
encompassing explanation for multi-systemic effects of the
disease.
Tissue Source
According to Chien et al. there are several disadvantages with
the use of post-mortem brain tissue in gene expression studies
(Chien et al., 2013). They point out that using fresh brain tissue
from living patients is not always practical, and as a surrogate for
brain tissue, several studies have instead utilized peripheral blood
cells and LCL. They also state that there is a moderate correlation
of gene expression has been reported between peripheral blood
cells and brain tissue in humans which supports the usefulness of
peripheral blood cells instead of brain-tissue for gene expression
studies. Yet Mahfouz et al. (2015), argue that due to the
nature of the pathology of ASD, which affects brain regions
and the connection between various brain regions, there are
advantages to post-mortem gene studies from brain tissue over
peripheral blood studies. Kuwano et al. concluded that gene
expression profiling of LCL are well documented because of their
homogeneity (Kuwano et al., 2011).
Segura et al. explained that their rationale to use blood as
opposed to post-mortem brain tissue was due to the limited
access of tissue from the central nervous system (CNS) in
humans (Segura et al., 2015). They also brought reports of a
potential correlation between neurotrophin expression in CNS
and the periphery, which would suggest that taking blood in
order to study neurotrophins would be similarly effective to using
brain tissue. Similarly, Pramparo et al. (2015) emphasized the
advantages of peripheral blood, and were successful in identifying
2765 genes from a peripheral blood source from a variety of
pathways including apoptosis, the immune response, and genes
involved in translation.
According to Hu et al. while studies that used brain tissue
to better understand the mechanistic basis for ASD could be
informative; this method of study is not an appropriate target
for diagnostic assays. They counter that diagnostic assays should
ideally be taken from easily obtainable samples such as the
patient’s blood (Hu et al., 2006). However, Talebizadeh et al.
acknowledge that LCL samples may not be ideal to use in order
to investigate brain-related genes, but they may still be helpful
for understanding at least a subset of brain-related changes
(Talebizadeh et al., 2014).
LIMITATIONS SPECIFIC TO ASD GENE
EXPRESSION STUDIES: A CRITICAL
APPRAISAL OF THE DATA
The clinical heterogeneity of ASD presents a challenge any
time studies attempt to find patterns across the spectrum.
Complicating matters even more, the ASD gene expression
studies relied on a variety of diagnostic methods to define ASD
(Tables 4A,B). The lack of consistency between the diagnostic
criteria and the subjectivity of the behavioral methods of
diagnosis limit the ability to extrapolate the data to the broader
ASD population.
Additionally, demographic variability between subjects and
between subjects and controls complicates analysis. Considering
that ASD is 4.5 times more common in males than females, the
ratio of subjects in each study is of great importance if it is meant
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to represent the broader ASD population. While some studies
took the disproportionate male incidence into consideration in
choosing their subjects, others did not. The clinical presentation
of ASD also varies by age. Therefore, significant age differences
between ASD subjects and controls such as those in the study by
Chien (Chien et al., 2013) deserve further attention.
CONCLUSION
One of the advantages of gene expression studies over whole
genome sequencing studies or Enzyme-Linked Immunosorbent
Assay (ELISA) based protein studies for ASD is that it allows
for broad screening for unique aspects of the disorder while
maintaining a level of specificity that the other modalities
cannot provide. In whole genome sequencing studies, millions
of base pairs are analyzed and often nothing significant is
found, or the few sporadic single nucleotide polymorphisms
(SNP’s) or copy number variants (CNV’s) lack any useful
context. While admittedly, more than 100 ASD-susceptibility
genes have been found, the utility of this information remains
elusive. In gene expression studies, on the other hand,
despite analyzing large amounts of genes, the thresholds for
differences in expression enable a level of specificity and the
ability to group specific genes together in order to identify
specific pathways. Approximately 12,000 genes were differentially
expressed between ASD compared to controls in gene expression
studies since 2011. Most of studies can be subdivided by the
source into three categories: brain (∼3500 dysregulated genes),
LCL (∼5600 dysregulated genes), and GI (∼2600 dysregulated
genes). More specifically, in the gene expression studies of
ASD surveyed, cell cycle, GI disease, immune function, and
neurogenesis, were found to be the most common implicated
pathways.
Most of the genes surveyed were shown to be consistently
down or up-regulated across different source types in different
studies. This strongly suggests that, in fact, these genes are not
coincidentally higher or lower in ASD but might actually be
active players in the underlying pathogenesis of the disorder.
Future Directions
Researchers might want to consider testing more than one
sample source (peripheral blood, intestine, olfactory stem cell,
and hair follicles) for each subject to help determine if up or
downregulation is consistent amongst tissue types. In the absence
of comparing across sample source types it remains unclear if
differences between subjects in gene regulation are due to the
different subjects or the different sample source.
Furthermore, researchers might consider including more
healthy mothers of children with ASD in the gene expression
studies and TD siblings in order to help isolate potential
immunogenetic processes. This might help clarify why certain
immune mechanisms affect only the child with ASD and not the
mother or the siblings. Another idea could be to analyze the blood
of daughters of women who have given birth to children with
ASD in order to test whether they too have abnormal levels of
certain proteins or immune markers that their healthy mothers
have. If found, the abnormal levels could suggest that the healthy
mother is passing something on to her daughter that would then
make her more susceptible to having a child with ASD herself.
Additionally, now that certain pathways have been identified
as being associated with ASD, researchers can work backwards
and look for other genes involved in those pathways and test
whether these specific genes play a role in ASD.
Finally, in order to help identify potential sub-groups of ASD,
it might be fruitful to study correlations between subsection
scores on ADOS and gene expression studies. This might
unravel the heterogeneity of ASD into individual strands whose
underlying pathology can be better understood at the genetic
and epigenetic levels in order to develop targeted therapeutic
approaches.
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